Loading
A phase 2/3 trial of RC148, CAPOX in colorectal cancer, run by RemeGen Co., Ltd., now recruiting.
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer is a phase 2/3 interventional study registered as NCT07462143 by RemeGen Co., Ltd., with 80 participants planned, started 2026-05-12 and due to reach its primary completion in 2027-05-12. Interventions recorded: RC148 (Dose 1) plus Capecitabine and Oxaliplatin, RC148 (Dose 2) plus Capecitabine and Oxaliplatin. Conditions listed: Colorectal (Colon or Rectal) Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/